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Protein Protection
from the Sun
New information reported by researchers at
the University of Texas Southwestern
Medical Center in Dallas could eventually
help scientists develop better ways to protect
against and treat the adverse effects of too
much sunlight. In a paper published in the
June 1999 issue of Molecular Cell, the
researchers demonstrated that the interac-
tion between a protein called Rad23 and a
protein complex known as the 26S protea-
some is important for the ability of yeast
cells to repair DNA damage caused by ultra-
violet (UV) light. Human cells contain very
similar proteins, so this finding may lead to
insights into how human skin responds to
UV exposure.
The study built on earlier work by
researchers from the Robert Wood
Johnson Medical School in Piscataway,
New Jersey, published
in the 12 February
1998 issue of Nature,
that first demonstrated
a physical interaction
between Rad23 and
the 26S proteasome.
The 26S proteasome is
a large, two-part com-
plex involved in the
degradation of many
different cellular pro-
teins: the 19S regulato-
ry complex is thought
to bind to damaged
proteins, unfold their
Sun spot. The site of interaction between a
protein and a proteasome is yielding clues to
the repair of DNA damage from UV light.
twisted lengths, and thread them into the
barrel-shaped 20S structure, where they are
degraded by protease enzymes.
The site of interaction between the 26S
proteasome and Rad23 appears to be
Rad23's ubiquitin (Ub)-like domain, a sec-
tion of the protein that physically resembles
true Ub, a small protein that connects to
other proteins and targets them to be
degraded by the 26S proteasome. (This does
not seem to be the case for the Ub-like
domain of Rad23, however; its function is
still not understood.) Other, earlier research
had shown that yeast missing the Rad23
protein or its Ub-like domain were more
sensitive to UV radiation. With the
Molecular Cell study, the Texas scientists
were able to show that the physical interac-
tion between Rad23's Ub-like domain and
the 26S proteasome is necessary for optimal
DNA repair to take place.
To investigate the relationship between
Rad23 and the 26S proteasome, the
researchers prepared yeast extracts that had
either the Rad23 full-length protein, no
Rad23 at all, or a Rad23 from which the Ub-
like domain had been deleted. Yeast with the
full-length Rad23 were found to repair UV
damage very well. Those without the Rad23
protein displayed almost no repair activity.
Those with the truncated version ofthe pro-
tein-in other words, those in which a
Rad23-proteasome interaction would be
impaired-were in the middle, with damage
being repaired half as well as with the full-
length protein.
Next, the scientists looked at whether
the 26S proteasome is important for DNA
repair in vitro. To explore the role of the
19S regulatory complex, they added to the
yeast extract an antibody to inhibit one of
the complex's subunits and examined the
consequences for DNA repair. Addition of
this antibody was found to inhibit 50% of
repair activity.
Antibodies against
unrelated proteins
had no effect on
repair activity, indi-
cating that the 26S
proteasome does
have a role in DNA
repair Eventually,
the Texas team's
findings may lead
to innovations in
the prevention
and treatment of
skin cancer.
Coauthor Steven
J. Russell says the 26S proteasome is already
being investigated as a drug target for wast-
ing diseases such as AIDS and cancer in
which the complex is overactive, degrading
proteins too quickly. Proteasome inhibitors
are also being investigated as protectants
against inflammation, which may be useful
in conditions such as arthritis and sepsis.
Russell says, "A couple ofrecent papers sug-
gest that drugs already in use may work in
part by inhibiting the proteasome in addition
to their known mechanism."
Russell continues, "Our ultimate goal is
to understand exactly how the proteasome
is involved in DNA repair. We need to
work out the details, but the implication is
that we have a novel mechanism ofprotea-
some action and a novel facet of the DNA
repair process." -Susan M. Booker
The Beat
Pinpointing Asthma
Researchers atthe U.S. Department of Energy's
Lawrence Berkeley National Laboratory in
Berkeley, California, have uncovered two genes
that influence an individual's susceptibility to
asthma using a novel way to determine if
specific genes are linked to diseases. The two
asthma-related interleukin genes, IL4 and IL13,
are located in the chromosome 5 region ofthe
human genome. Study scientists believe that
finding a wayto limit the activity ofthese genes
will reduce the probability of asthma attacks.
In the study, published in the 1 October
1999 issue of Nature Genetics, the researchers
divided a several-million-base-pair region of
chromosome 5 into large chunks and then
introduced these pieces separately into the
genomes of mice. The scientists then matched
the physical characteristics ofthe mice with the
same characteristics exhibited by human asthma
sufferers to pinpoint IL4 and IL13 as
susceptibility genes
Ending River Blindness
A World Health Organization (WHO) program
to eradicate onchocerciasis, or river blindness,
has proven hugely successful. River blindness
affects millions of people in West Africa.
According tothe WHO, the program has so
far saved 100,000 people from the immediate
risk of contracting the disease and has
prevented the potential infection of 12 million
children. Also due to these efforts, over one
million people infected with river blindness
have been successfully treated.
Regulating Medical Recycling
On 1 November 1999 the U.S. Food and Drug
Administration (FDA) announced proposals for
new rules regarding the reuse ofdisposable
medical devices including surgical clamps,
cardiac catheters, and angioplasty balloons.
Criticsallege
this growing
practice, adopted
by some hospitals
as a cost-cutting
measure, poses
_ SN ~~~~~health risks. The
hospitals and companies that resterilize the
items counter that the manufacturers of the
items label them as disposable only to increase
sales.
The FDA has been brought into the
debate by Congress to determine which of
the devices can be safely reused and how
many times, and to classify disposable medical
devices using these determinations. Under the
proposed regulations, hospitals would have to
register with the FDA if they choose to reuse
these devices.
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